In today’s recent session, 0.48 million shares of the Relmada Therapeutics Inc (NASDAQ:RLMD) have been traded, and its beta is 0.56. Most recently the company’s share price was $0.69, and it changed around $0.03 or 4.76% from the last close, which brings the market valuation of the company to $23.02M. RLMD at last check was trading at a discount to its 52-week high of $4.47, offering almost -547.83% off that amount. The share price’s 52-week low was $0.24, which indicates that the recent value has risen by an impressive 65.22% since then. We note from Relmada Therapeutics Inc’s average daily trading volume that its 10-day average is 1.04 million shares, with the 3-month average coming to 1.81 million.
Relmada Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 3 recommended RLMD as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Instantly RLMD has been showing a green trend so far today with a performance of 4.76% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.6981 on recent trading dayincreased the stock’s daily price by 1.16%. The company’s shares are currently up 33.37% year-to-date, but still up 16.16% over the last five days. On the other hand, Relmada Therapeutics Inc (NASDAQ:RLMD) is 94.20% up in the 30-day period. We can see from the shorts that 2.03 million shares have been sold at a short interest cover period of 0.53 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 90.14% from its current value. Analyst projections state that RLMD is forecast to be at a low of $2 and a high of $8.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 0.68%. Relmada Therapeutics Inc earnings are expected to increase by 27.17% in 2025, but the outlook is positive 31.28% per year for the next five years.
RLMD Dividends
Relmada Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-11.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 17.03% of Relmada Therapeutics Inc shares, and 33.47% of them are in the hands of institutional investors. The stock currently has a share float of 40.34%. Relmada Therapeutics Inc stock is held by 56.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 16.6593% of the shares, which is about 1.26 million shares worth $3.77 million.
DEEP TRACK CAPITAL, LP, with 16.3686% or 1.23 million shares worth $3.7 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND were the top two Mutual Funds as of Dec 31, 2024 . The former held 851.92 shares worth $0.59 million, making up 8.61% of all outstanding shares. On the other hand, Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND held roughly 456.4 shares worth around $0.32 million, which represents about 4.61% of the total shares outstanding.
